Speaker：Zhetao Zheng（郑哲涛）Junxiao Hou（侯郡潇）Aoyue Mao（茅傲岳）

Time：10:00 - 13:00

Location：Room 311, Kezhen Wang Building

Abstract:

As we know, there are many genetic diseases arising from point mutations. Fortunately, the development and application of genome-editing technologies have brought us a new sense of hope and vision for curing such diseases. In 2016, the group of David Liu firstly reported a new approach to genome editing that enables the direct, irreversible conversion of one target DNA base into another in a programmable manner, without requiring dsDNA backbone cleavage or a donor template. This new approach which is based on CRISPR-mediated deaminase systems, including cytosine base editors (CBE) and adenine base editors (ABE), has brought us a new sense of hope and vision for curing monogenic disease, like DMD.

Guest information:

1. Dr. Xing Chang

http://sourcedb.sibs.cas.cn/zw/rck/201206/t20120619_3602537.html

2. Dr. Yulong Li (PKU)

1. Rees H A, Liu D R. Base editing: precision chemistry on the genome and transcriptome of living cells[J]. Nature Reviews Genetics, 2018: 1.

DOI: https://doi.org/10.1038/s41576-018-0059-1

DOI: https://doi.org/10.1016/j.molcel.2018.09.002

2. Ryu S M, Koo T, Kim K, et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy[J]. Nature Biotechnology, 2018, 36(6): 536.

DOI: https://doi.org/10.1038/nbt.4148